Participated · Series D · Aug 2024

Neptune Medical develops advanced medical devices with a primary focus on gastrointestinal robotics. The company’s mission is to enhance patient outcomes through innovative technology and collaborative partnerships. Neptune recently completed a $97M Series D financing, which the company says will strengthen its focus on GI robotics and expansion into robotics for GI disease. Neptune appointed medical robotics pioneer Dr. Fred Moll as Chairman of the Board, underscoring its emphasis on medical-robotics expertise. The company also spun out its subsidiary, Jupiter Endovascular, enabling that business to concentrate on a novel endovascular technology platform. Jupiter Endovascular is developing a new class of endovascular procedures to bring the precision and control of direct surgical access to catheter-based interventions.

Participated · Equity · Jan 2024

Eximis Surgical is developing the Eximis Laparoscopic Specimen Removal System to provide fast, fully contained segmentation and removal of large specimens through small laparoscopic incisions. The platform is designed to keep incisions small throughout minimally invasive procedures and aims to fill a clinical gap in specimen removal. The company announced it secured $8.7 million in financing to support its development and regulatory progress. Proceeds will be used to fund U.S. regulatory activities for the system. The Eximis system is not yet available for sale in the U.S. Eximis is based in Louisville, Colo., and its board includes co-founder and CEO Donna Ford-Serbu alongside industry executives and investors. Eximis Surgical develops the Eximis Laparoscopic Specimen Removal System, which is designed to keep incisions small during minimally invasive procedures by providing contained specimen segmentation and removal. The system integrates multiple containment bags and a novel cutting technology that eliminates the need for sharps during segmentation. Led by co‑founder and CEO Kristin Johnson, the company is preparing for regulatory and commercial milestones. The device is not currently approved for commercial use. Eximis intends to use new capital to pursue U.S. regulatory approval and fund the commercial launch of the system. The company is headquartered in Louisville, Colorado.

Led · Series E · May 2010

Small Bone Innovations (SBi) develops and commercializes implants and technologies for small bones and joints, with its flagship STAR total ankle replacement and an upper and lower limb product portfolio. The company was founded in 2004 by Viscogliosi Brothers and has facilities in New York, NY; Morrisville, PA; Péronnas, France; Donaueschingen, Germany; and Kuala Lumpur, Malaysia, and has sold products in 46 countries. Management reports positive sales and business performance this year, with continued revenue growth and substantial reductions in operating expenses. SBi plans a more aggressive buildup of its direct sales organization in the United States to drive further adoption of the STAR ankle. The company is using new financing to refinance existing indebtedness and provide working capital to accelerate sales across its portfolio. Small Bone Innovations focuses on devices and treatments for small-bone joint repair and trauma reconstruction across the hand, upper limb and lower extremity. Its product portfolio includes the STAR™ total ankle joint replacement system and a stable core upper limb arthroplasty and trauma reconstruction line. The company plans to use proceeds from the latest financing to continue driving growth of the STAR ankle system and support its existing product portfolio. SBi was founded in 2004 and previously raised $144m in Series D and Series C rounds in June 2009. The company operates facilities in New York, NY; Morrisville, PA; Bourg-en-Bresse, France; Donaueschingen, Germany; and Kuala Lumpur, Malaysia. The recent capital infusion is intended to support continued commercial and product growth in its targeted small-bone joint markets. Small Bone Innovations develops orthopedic technologies and treatments focused on small bones and joints, notably its S.T.A.R.® total ankle replacement system. The company plans a worldwide rollout of the S.T.A.R. system, using new capital to fund inventory and expand surgeon education and training. Management says proceeds will also support new and expanded product offerings for both upper and lower limb anatomies and related clinical studies. SBi operates facilities in New York, Morrisville (PA), Bourg-en-Bresse (France), Donaueschingen (Germany) and Kuala Lumpur (Malaysia). The company distributes its products and technologies in more than 50 countries. Anthony G. Viscogliosi is Chairman & CEO. Small Bone Innovations (SBi) develops technologies and treatments for small bones and joints, with products for upper and lower limb anatomies. The company plans to introduce new products and improved versions in 2010 and to develop and initiate several studies to support clinical understanding of its portfolio. SBi closed a $30M credit facility to accelerate business expansion and refinance existing indebtedness. The facility allowed the company to fully repay approximately $13M of its existing debt. In conjunction with the credit facility closing, Helmut D. Link and the investor group of Link America, Inc. made an equity investment in SBi. The company was founded in 2004 and operates facilities in New York, NY; Morrisville, PA; Bourg-en-Bresse, France; Donaueschingen, Germany; and Kuala Lumpur, Malaysia.